December 20, 2006 – OptiNose is pleased to announce the results of a Phase I study in 12 patients evaluating the effects of intranasal sumatriptan in subjects suffering from migraine. The study compared the effects of intranasal sumatriptan nasal spray delivered by the OptiNose device with a sub-cutaneous reference dose on glyceryltrinitrate-induced migraine in migraineurs, using EEG biomarkers.
The results demonstrate that sumatriptan at doses of 10 mg or 20 mg delivered intranasally by the OptiNose powder nasal drug delivery device is rapidly absorbed with similar effects on the EEG profile to a dose of 6mg administered subcutaneously.
About OptiNose Inc.
OptiNose is a drug delivery company with breakthrough bi-directional nasal technology set to transform the static nasal drug delivery market. Founded in 2000, OptiNose’s devices are designed to deliver intranasal drugs to target regions of the nasal cavity, including the sinuses and the olfactory region while preventing lung deposition. The company offers both single and multi-use intranasal delivery devices for liquid and powder formulations. The technology has been successfully tested in a number of clinical trials with results confirming the superiority of the technology compared to traditional nasal sprays. Investors in OptiNose include Avista Capital Partners in New York, WFD Ventures LLC located in New York and Entrepreneurs Fund LP based in Jersey, Channel Islands. For more information please visit www.OptiNose.com.
About Bi-directional Nasal Delivery Technology
OptiNose’s bidirectional nasal delivery technology significantly improves delivery to the targeted sites deep into the nose. While exhaling into the device, the soft palate automatically closes off the nasal cavity completely. The breath enters one nostril through a sealing nozzle and triggers the release of drug particles into the airflow. This action causes the narrow nasal passages to expand and carry these particles beyond the nasal valve to targeted sites. After delivering drug particles to the targeted sites, the air flow then exits the nasal cavity through the other nasal passage in the opposite direction.
Contact:
Darren Brandt
(212) 446-1861
dbrandt@sloanepr.com
Dan Zacchei
(212) 446-1882
dzacchei@sloanepr.com